Insider Transactions in Q1 2021 at Revance Therapeutics, Inc. (RVNC)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Abhay Joshi COO, President of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
1,354
-1.04%
|
$36,558
$27.73 P/Share
|
|
Mar 15
2021
|
Dwight Moxie CLO & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
2,881
-5.5%
|
$77,787
$27.73 P/Share
|
|
Mar 08
2021
|
Olivia C Ware Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,408
+50.0%
|
-
|
|
Mar 04
2021
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-7.45%
|
$827,975
$25.43 P/Share
|
|
Mar 01
2021
|
Carey O Connor Kolaja Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,294
+50.0%
|
-
|
|
Feb 15
2021
|
Abhay Joshi COO, President of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
4,848
-1.82%
|
$135,744
$28.97 P/Share
|
|
Feb 15
2021
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,410
-1.78%
|
$67,480
$28.97 P/Share
|
|
Feb 15
2021
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,657
-1.87%
|
$74,396
$28.97 P/Share
|
|
Feb 02
2021
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,715
+4.78%
|
-
|
|
Feb 02
2021
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
19,346
+26.98%
|
-
|
|
Feb 02
2021
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
22,620
+24.05%
|
-
|
|
Feb 02
2021
|
Dustin S Sjuts President |
BUY
Grant, award, or other acquisition
|
Direct |
22,620
+24.98%
|
-
|
|
Feb 02
2021
|
Abhay Joshi COO, President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
22,620
+14.39%
|
-
|
|
Feb 02
2021
|
Aubrey Rankin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,905
+12.99%
|
-
|
|
Feb 01
2021
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-6.94%
|
$827,975
$25.95 P/Share
|